AC Immune and Lilly announce license and collaboration agreement

AC Immune SA (NASDAQ: ACIU) and Eli Lilly and Company (NYSE:LLY) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases. Under the terms of the agreement, AC Immune will receive an upfront payment of CHF 80 million as well as USD 50 million in exchange for a note, convertible to equity at a premi-um. AC Immune is also eligible to receive CHF 60 million in potential near-term development milestones, as well as other potential development, regulatory and commercial milestones up to approximately CHF1.7 billion, and tiered royalty payments in the low double digits. VISCHER AG advised AC Immune as to Swiss law matters along Davis Polk & Wardwell LLP advising on US law matters.

The team at VISCHER was led by Matthias Staehelin (Partner), with Christian Wyss (Partner) and Vincent Reardon (Senior Associate) all Corporate and Nadia Tarolli (Partner, Tax).

Blogs and special topics

Our specialists blog and websites on selected topics will keep you informed of the latest developments and discussions.